INVESTOR AGREEMENTInvestor Agreement • November 5th, 2020 • Solid Biosciences Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledNovember 5th, 2020 Company Industry JurisdictionTHIS INVESTOR AGREEMENT (this “Agreement”) is made as of October 22, 2020, by and between Solid Biosciences Inc., a Delaware corporation (the “Company”), and Ultragenyx Pharmaceutical Inc., a Delaware corporation (the “Investor”).
INVESTOR AGREEMENT BY AND BETWEENInvestor Agreement • August 6th, 2019 • Regeneron Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledAugust 6th, 2019 Company Industry JurisdictionTHIS INVESTOR AGREEMENT (this “Agreement”) is made as of April 8, 2019, by and between Regeneron Pharmaceuticals, Inc. (the “Investor”), a New York corporation with its principal place of business at 777 Old Saw Mill River Road, Tarrytown, New York 10591, and Alnylam Pharmaceuticals, Inc. (the “Company”), a Delaware corporation with its principal place of business at 300 Third Street, Cambridge, Massachusetts 02142.
INVESTOR AGREEMENT By and BetweenInvestor Agreement • August 6th, 2019 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledAugust 6th, 2019 Company Industry JurisdictionTHIS INVESTOR AGREEMENT (this “Agreement”) is made as of April 8, 2019, by and between Regeneron Pharmaceuticals, Inc. (the “Investor”), a New York corporation with its principal place of business at 777 Old Saw Mill River Road, Tarrytown, New York 10591, and Alnylam Pharmaceuticals, Inc. (the “Company”), a Delaware corporation with its principal place of business at 300 Third Street, Cambridge, Massachusetts 02142.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Triple asterisks denote omissions. INVESTOR AGREEMENTInvestor Agreement • June 5th, 2015 • Macrogenics Inc • Pharmaceutical preparations • Delaware
Contract Type FiledJune 5th, 2015 Company Industry JurisdictionTHIS INVESTOR AGREEMENT (this "Agreement") is made as of December 19, 2014, by and among Johnson & Johnson Innovation-JJDC, Inc., a New Jersey corporation with its principal place of business at 410 George Street, New Brunswick, New Jersey 08901 ("Investor") and MacroGenics, Inc. (the "Company"), a Delaware corporation with its principal place of business at 9640 Medical Center Drive, Rockville, MD 20850.